跳至主要内容
临床试验/NCT00201344
NCT00201344终止3 期

A Phase III Study of Radiotherapy With or Without Adjuvant Chemotherapy in Advanced Stage Nasopharyngeal Carcinoma Patients

National Health Research Institutes, Taiwan2 个研究点 分布在 1 个国家目标入组 320 人开始时间: 1994年11月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
终止
发起方
入组人数
320
试验地点
2
主要终点
overall survival, relapse free survival,distant metastasis and local-regional control rates.

研究概览

简要总结

  • To investigate the efficacy of adjuvant PFL chemotherapy after radiotherapy vs radiotherapy alone in AJC stage IV nasopharyngeal carcinoma patients. The endpoints of the study includes : overall survival, relapse free survival, distant metastasis and local-regional control rates.
  • To evaluate the toxicities of the two treatment methods.

详细描述

The head and neck contracts study tested induction and maintenance chemotherapy in patients with advanced head and neck cancers.There were no significant differences in survival between the two groups, but disease free survival was prolonged in the maintenance arm and not in the induction arm. Time to and frequency of distant metastases as the first site of relapse were significantly better for those on the maintenance arm. Many trials, designed several years ago, delivered single agent chemotherapy and were not particularly intensive. Most clinical trials were dealing with a heterogenous group of head and neck cancer patients. We felt that a better choice of adjuvant chemotherapy on cancers should include: (1) localized cancers with high metastatic potential following effective local treatment; (2) effective chemotherapy available; (3) chemotherapy should be intensive and effective enough to avoid the development of drug resistance. Of course, NPC had long been regarded as one of the most suitable head and neck cancers that may benefit from adjuvant chemotherapy due to its unique high response rate to chemotherapy and high metastatic potential after radiotherapy for localized, advanced staged disease.

If radiotherapy plus adjuvant chemotherapy can improve the treatment results of standard radiotherapy by increasing the survival rate, decreasing the metastatic rate and local recurrence rate, then many NPC patients may benefit.

Therefore, we propose this phase III study of radiotherapy with or without adjuvant PFL chemotherapy in advanced stage NPC patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
— 至 70 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients must have histologically proven nasopharyngeal carcinoma who have just completed curative radiotherapy treatment.
  • Original stage must be stage IV disease (M0)
  • Patients must have a complete response, partial response or stable disease assessed 4 weeks after radiotherapy.
  • Performance status scale ECOG grade 0,
  • Creatinine ≦ 1.5mg/dl and bilirubin ≦ 2.0mg/dl, WBC ≧ 3,000/mm3 and PLT ≧ 100,000/mm3,or Creatinine Clearance > 45ml/min if Creatinine > 1.5mg/dl.
  • Patients must be younger than 70 year-old.
  • Patients must give signed informed consent.

排除标准

  • Patients had progressive disease after radiotherapy
  • Patients had evidence of distant metastasis.
  • Patients had completed radiotherapy for more than 7 weeks.
  • The presence of life-threatening illness
  • History of prior malignancy excluding basal cell carcinoma or squamous carcinoma of the skin or in-situ cervical cancer within 3 years of the diagnosis of NPC cancer.
  • Previous chemotherapy.
  • Pregnancy.

结局指标

主要结局

overall survival, relapse free survival,distant metastasis and local-regional control rates.

次要结局

  • toxicities of the two treatment methods.

研究者

发起方
National Health Research Institutes, Taiwan
申办方类型
Other

研究点 (2)

Loading locations...

相似试验

进行中(未招募)
3 期
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the BodyClinical Stage IV Esophageal Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8Clinical Stage IVA Gastric Cancer AJCC v8Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8Clinical Stage IVB Gastric Cancer AJCC v8Metastatic Esophageal AdenocarcinomaMetastatic Gastric AdenocarcinomaOligometastatic Esophageal AdenocarcinomaOligometastatic Gastric AdenocarcinomaPathologic Stage IV Esophageal Adenocarcinoma AJCC v8Pathologic Stage IV Gastric Cancer AJCC v8Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
NCT04248452ECOG-ACRIN Cancer Research Group314
Unknown
3 期
Oral Cancer Adjuvant Therapy (OCAT) TrialMouth Neoplasms
NCT00193843Tata Memorial Hospital900
进行中(未招募)
3 期
TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal CarcinomaNasopharyngeal Carcinoma
NCT03306121Sun Yat-sen University322
已完成
3 期
Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma PatientsOral CavitySquamous Cell Carcinoma
NCT00201383National Health Research Institutes, Taiwan161
进行中(未招募)
2 期
Phase II/III Study Compare Adjuvant Chemoradiotherapy, Radiotherapy and Surgery Alone for Esophageal CarcinomaEsophageal NeoplasmsEsophageal Cancer
NCT02279134Zefen Xiao360